PBYI Quote, Financials, Valuation and Earnings

NovaBay Pharmaceuticals has a net margin of 6.46% compared to Puma Biotechnology's net margin of -49.65%. Puma Biotechnology's return on equity of 52.9% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Puma Biotechnology has a consensus price target of $3.00, signalling downside risk potential of -13.04%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 41.67%. Given that NovaBay Pharmaceuticals has higher upside potential than Puma Biotechnology, analysts believe NovaBay Pharmaceuticals is more attractive than Puma Biotechnology.

Puma Biotechnology has a beta of 1.289, which suggesting that the stock is 28.93% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.427, suggesting its less volatile than the S&P 500 by 57.305%.

Puma Biotechnology has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Puma Biotechnology pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Puma Biotechnology quarterly revenues are $46M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Puma Biotechnology's net income of $3M is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, Puma Biotechnology's price-to-earnings ratio is 4.48x while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Puma Biotechnology is 0.73x versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Nanoviricides has a net margin of 6.46% compared to Puma Biotechnology's net margin of --. Puma Biotechnology's return on equity of 52.9% beat Nanoviricides's return on equity of --.

Puma Biotechnology has a consensus price target of $3.00, signalling downside risk potential of -13.04%. On the other hand Nanoviricides has an analysts' consensus of -- which suggests that it could grow by 348.28%. Given that Nanoviricides has higher upside potential than Puma Biotechnology, analysts believe Nanoviricides is more attractive than Puma Biotechnology.

Puma Biotechnology has a beta of 1.289, which suggesting that the stock is 28.93% more volatile than S&P 500. In comparison Nanoviricides has a beta of 0.913, suggesting its less volatile than the S&P 500 by 8.749%.

Puma Biotechnology has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nanoviricides offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Puma Biotechnology pays -- of its earnings as a dividend. Nanoviricides pays out -- of its earnings as a dividend.

Puma Biotechnology quarterly revenues are $46M, which are larger than Nanoviricides quarterly revenues of --. Puma Biotechnology's net income of $3M is higher than Nanoviricides's net income of -$2.2M. Notably, Puma Biotechnology's price-to-earnings ratio is 4.48x while Nanoviricides's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Puma Biotechnology is 0.73x versus -- for Nanoviricides. Usually stocks with elevated PS ratios are considered overvalued.

Oragenics has a net margin of 6.46% compared to Puma Biotechnology's net margin of --. Puma Biotechnology's return on equity of 52.9% beat Oragenics's return on equity of --.

Puma Biotechnology has a consensus price target of $3.00, signalling downside risk potential of -13.04%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 589.72%. Given that Oragenics has higher upside potential than Puma Biotechnology, analysts believe Oragenics is more attractive than Puma Biotechnology.

Puma Biotechnology has a beta of 1.289, which suggesting that the stock is 28.93% more volatile than S&P 500. In comparison Oragenics has a beta of 0.938, suggesting its less volatile than the S&P 500 by 6.243%.

Puma Biotechnology has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Puma Biotechnology pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.

Puma Biotechnology quarterly revenues are $46M, which are larger than Oragenics quarterly revenues of --. Puma Biotechnology's net income of $3M is higher than Oragenics's net income of -$2.2M. Notably, Puma Biotechnology's price-to-earnings ratio is 4.48x while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Puma Biotechnology is 0.73x versus 1.39x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of 6.46% compared to Puma Biotechnology's net margin of --. Puma Biotechnology's return on equity of 52.9% beat Theriva Biologics's return on equity of --.

Puma Biotechnology has a consensus price target of $3.00, signalling downside risk potential of -13.04%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1398.61%. Given that Theriva Biologics has higher upside potential than Puma Biotechnology, analysts believe Theriva Biologics is more attractive than Puma Biotechnology.

Puma Biotechnology has a beta of 1.289, which suggesting that the stock is 28.93% more volatile than S&P 500. In comparison Theriva Biologics has a beta of 0.848, suggesting its less volatile than the S&P 500 by 15.165%.

Puma Biotechnology has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Puma Biotechnology pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

Puma Biotechnology quarterly revenues are $46M, which are larger than Theriva Biologics quarterly revenues of --. Puma Biotechnology's net income of $3M is higher than Theriva Biologics's net income of -$4.3M. Notably, Puma Biotechnology's price-to-earnings ratio is 4.48x while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Puma Biotechnology is 0.73x versus 0.33x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.